Eli Lilly and Co.'s (LLY) fourth-quarter net income slid to $858.2 million or $0.77 per share from year-ago quarter's $1.17 billion or $1.05 per share, with non-GAAP earnings declining to $968.9 million or $0.87 per share from $1.23 billion or $1.11 per share last year, which is mainly driven by lower operating income. On average, 18 analysts polled by Thomson Reuters expected earnings per share of $0.81 for the quarter. Analysts' estimates typically exclude one-time items.
Excluding the impact of changes in foreign exchange rates, earnings per share would have decreased nearly 23 percent.
Worldwide total revenue for the latest quarter was $6.05 billion, a decrease of 2 percent from $6.19 billion in the previous year, driven by Zyprexa and Gemzar patent expirations, partially offset by growth in other products. Analysts estimated revenues of $5.90 billion for the quarter.
Further, Eli Lilly confirmed its 2012 guidance, still expecting earnings between $3.10 and $3.20 per share on both, a reported and adjusted basis, and revenues of $21.8 billion to $22.8 billion. Analysts estimate earnings of $3.19 per share on revenue of $22.34 billion for the full year 2012.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.